News
Kommentar zu Namaste als Blogbeitrag
Meine Einschätzung vom 19.06.17 zu Namaste hat sich bis heute im Wert verzwanzigfacht. Die Aktie war in meinem Einschätzungsdepot zunächst stark übergewichtet, weil die Firma vom Markt viel zu....
Quantum Genomics to Present at Biotech Showcase 2018
Quantum Genomics (Euronext Growth - FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat....
Can This Beaten-Down Marijuana Stock Roar Back in 2018?
There was good news and bad news for Zynerba Pharmaceuticals (NASDAQ: ZYNE) in 2017. First, the good news: The cannabinoid-focused biotech stock is up more than 90% over the last three months.....
Roche Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
On the heels of Bayer AG (NASDAQOTH: BAYRY) licensing Loxo Oncology's (NASDAQ: LOXO) fusion-targeting cancer drug, Roche Holdings (NASDAQOTH: RHHBY) is acquiring Ingynta (NASDAQ: RXDX), a company....
Bayer Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
On the heels of Bayer AG (NASDAQOTH: BAYRY) licensing Loxo Oncology's (NASDAQ: LOXO) fusion-targeting cancer drug, Roche Holdings (NASDAQOTH: RHHBY) is acquiring Ingynta (NASDAQ: RXDX), a company....
Why Corcept Therapeutics Shares Climbed 10.8% Today
After news broke that shares will soon be included in the S&P Small Cap 600 index, Corcept Therapeutics' (NASDAQ: CORT) stock price jumped by 10.8% today.The addition to the S&P 600 Small....
Portola Pharmaceuticals Gets a Surprise Present From the FDA
The FDA approved Portola Pharmaceuticals' (NASDAQ: PTLA) first commercial drug, Bevyxxa, in June, but changes to its manufacturing process resulted in the filing of a prior approval supplement....
What to Expect From Corbus Pharmaceuticals in 2018
For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than....
Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug
Aerie Pharmaceuticals' (NASDAQ: AERI) Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to....
Why Novavax Stock Is Tumbling Today
Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be....
Is Aurinia Pharmaceuticals a Buy?
There's good news and bad news for Aurinia Pharmaceuticals (NASDAQ: AUPH) shareholders. Let's start with the good news. The company has had a fantastic 2017, with its stock price soaring more than....
Delivery Hero: Indiengeschäft wird verkauft
Der Online-Essenslieferant Delivery Hero meldet heute den Verkauf seiner Plattform „footpanda Indien“ an die indische Plattform Ola. Den Verkaufserlös erhält Delivery Hero in Ola-Anteilen. Damit....
3 Growth Stocks to Own in 2018
With U.S. stocks at all-times highs, it can be a serious challenge to find growth vehicles that are still worth buying at these levels. To do so, I think investors may want to try to mine the....
Is Cara Therapeutics, Inc. a Buy?
Small-cap biotech Cara Therapeutics (NASDAQ: CARA) is working to commercialize a drug to combat pain -- but the stock has managed to inflict a different sort of suffering on its investors in....
Here's Why GlycoMimetics Could Become a Takeover Target
Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next....
3 Top Small-Cap Stocks to Buy in December
Small-cap stocks are riskier than their blue-chip peers, but they can also deliver incredible gains. The trick is finding solid businesses that the rest of the market is overlooking, putting your....
BOIRON : Acquisition of trademarks and patents
The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes....
BOIRON : Acquisition de marques et brevets
Les Laboratoires BOIRON ont acquis auprès de la société suisse ALKANTIS les marques et brevets relatifs à son dispositif médical à visée antalgique, anti-inflammatoire et anti-œdémateuse....
Why ImmunoGen, Inc. Jumped Higher Today
Shares of ImmunoGen (NASDAQ: IMGN) closed up 12% as the American Society of Hematology (ASH) meeting wraps up. The biotech presented over the weekend, which shouldn't be affecting the price of....
5 Biotech Buyout Candidates for 2018
With the Republican tax plan steaming through both houses of Congress, 2018 is shaping up to be a banner year in terms of consolidation for the biotechnology industry. Biopharmaceutical....
Here's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November
Shares of Inovio Pharmaceuticals Inc. (NASDAQ: INO), a biopharmaceutical company developing vaccines, fell 21.3% in November according to data from S&P Global Market Intelligence. Despite....
QUANTUM GENOMICS : Symposium Quantum Genomics sur les inhibiteurs de l'aminopeptidase A cérébrale à l'occasion des 37èmes Journées de l'hypertension artérielle à Paris
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), société biopharmaceutique spécialisée dans le développement d'une nouvelle classe de médicaments agissant directement sur le cerveau....
Here's Why GlycoMimetics Is Soaring 24.3% Higher Today
After unveiling updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML), GlycoMimetics (NASDAQ: GLYC) shares are surging 24.3% as of noon EST....
Here's Why Omeros Corporation Is Gaining More Ground Today
Shares of Omeros Corporation (NASDAQ: OMER) rose as high as 10.8% this morning after the biotech announced a U.S. Food and Drug Administration approval that expands its commercial-stage drug to....
3 Stocks to Hold for the Next 20 Years
As Warren Buffett has said, "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." For long-term investors, this rings especially true, as a great....